Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs

Conventional DMARDs such as MTX are the mainstay of treatment for patients with RA. However, failure to achieve adequate disease control in many patients, even with combination therapy, has spurred the development of agents that target various immune mediators involved in the disease process. In the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Rheumatology (Oxford, England) England), 2012-07, Vol.51 Suppl 5 (suppl 5), p.v12-v21
Hauptverfasser:	Pavelka, Karel, Kavanaugh, Arthur F, Rubbert-Roth, Andrea, Ferraccioli, Gianfranco
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy B-Lymphocytes - drug effects Clinical Trials, Phase III as Topic Cytokines - drug effects Drug Therapy, Combination Humans Immunosuppressive Agents - therapeutic use T-Lymphocytes - drug effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!